Abstract

The invention provides a combination therapy comprising a bacterial strain for treating or preventing cancer.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 35/00 - Antineoplastic agents
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Provided are compositions comprising a bacterial strain of the genus Bacteroides, for use in a method of increasing the microbiota diversity and/or inducing stability of the microbiota of a subject.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

The invention provides compositions comprising a bacterial strain of the genus Fusicatenibacter and their use in medicine.

IPC Classes  ?

• A61K 35/74 - Bacteria

Abstract

The invention relates to bacterial strains for treating cancer.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 35/00 - Antineoplastic agents

Abstract

The invention is in the field of bacterial strains isolated from the mammalian digestive tract and the use of such strains, and compositions comprising these strains, in the treatment of disease.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 35/00 - Antineoplastic agents
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/46 - Streptococcus
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention is in the field of bacterial strains isolated from the mammalian digestive tract and the use of such strains, and compositions comprising these strains, in the treatment of disease.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 35/00 - Antineoplastic agents
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/46 - Streptococcus
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor

Abstract

The invention provides compositions comprising one or more bacterial strains for treating or preventing a central nervous system disease or disorder.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Parabacteroides, for use in a method of treating or preventing cancer in a subject; wherein the cancer comprises oncogenic ERK signalling.

IPC Classes  ?

• A61K 35/74 - Bacteria

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing lung injury or lung disease.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

A composition comprising a bacterial strain of the species Enterococcus durans, for use in a method of treating or preventing a central nervous system disorder or condition.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12R 1/46 - Streptococcus

Abstract

The anchor disc device supports and anchors an umbrella and includes a tube post to receive the free end of the pole of a beach umbrella with an anchor disc portion attached to the free end of the tube post. An end cap is installed in the free end of an extension of the anchor disc portion. The anchor disc portion includes an outwardly extending flange for engagement with sand into which the device is buried to help avoid disengagement of the umbrella from the sand from wind and the like. For removal, the umbrella is rotated in large circular motions to form a cone-shaped hole after which the umbrella and connected anchor disc device can be removed. The anchor disc device can then be detached from the umbrella, if desired.

IPC Classes  ?

• E04H 12/22 - Sockets or holders for poles or posts
• A45B 23/00 - Other umbrellas

Abstract

The invention provides compositions comprising bacterial strains and the use of such compositions in the treatment of disease, including in central nervous system disorders.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein are processes for providing a concentrated biomass with a high concentration of viable bacteria. The invention also provides compositions obtained by these processes.

IPC Classes  ?

• C12N 1/04 - Preserving or maintaining viable microorganisms
• A61K 35/66 - Microorganisms or materials therefrom

Abstract

Fusicatenibacter Fusicatenibacter and their use in medicine.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

FusicatenibacterFusicatenibacter and their use in medicine.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention provides pharmaceutical compositions comprising bacteria and the use of such compositions in the treatment of disease.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• C12R 1/01 - Bacteria or actinomycetales
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The invention provides compositions comprising one or more bacterial strains for treating or preventing sensory hypersensitivity.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention provides compositions comprising commensal bacterial strains and organic acids and the uses thereof in the treatment of diseases.

IPC Classes  ?

• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• A61K 35/74 - Bacteria
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 1/20 - BacteriaCulture media therefor
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The invention provides a composition comprising a bacterial strain of the genus Megasphaera, for use in the treatment or prevention of a disorder characterised by serotonin deficiency.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/24 - Antidepressants

Abstract

The invention provides a composition comprising a bacterial strain of the genus Parabacteroides, for use in a method of treating or preventing cancer in a subject; wherein the cancer comprises oncogenic ERK signalling.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention provides a composition comprising a strain of a bacteria for use in the treatment or prevention of a Gram-positive bacterial infection in a subject, wherein the strain produces valeric acid.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents

Abstract

The invention provides compositions comprising bacterial strains for use as a vaccine adjuvant; for use in treating, preventing or delaying immunosenescence; or for use in enhancing a cell therapy, such as CAR-T. The invention also provides vaccine compositions comprising bacterial strains and one or more antigens.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Blautia productaBlautia coccoidesBlautia coccoides, for use in therapy.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 11/06 - Antiasthmatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided are compositions comprising a bacterial strain of the genus Bacteroides, for use in a method of increasing the microbiota diversity and/or inducing stability of the microbiota of a subject.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The invention provides compositions comprising a viable bacterial strain of the genus Pediococcus, for use in treating or preventing an inflammatory or autoimmune disease

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/06 - Antiasthmatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The invention provides a composition comprising a bacterial strain for use in stimulating the immune system in a subject.

IPC Classes  ?

• A61K 35/66 - Microorganisms or materials therefrom
• A61P 37/04 - Immunostimulants

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing lung injury or lung disease.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The invention provides compositions comprising bacterial strains for use in therapy.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The invention provides an enteric dosage form comprising a live biotherapeutic product.

IPC Classes  ?

• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61K 35/74 - Bacteria
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

This invention is in the field of compositions comprising bacterial strains isolated from the mammalian digestive tract and the use of such compositions in the treatment of disease.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Megasphaera Megasphaera, for use in the treatment or prevention of an autoimmune or inflammatory disorder or cancer

IPC Classes  ?

• A61K 35/74 - Bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/06 - Antiasthmatics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 17/06 - Antipsoriatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

MegasphaeraMegasphaera, for use in stimulating the immune system in subject.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 39/02 - Bacterial antigens
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/06 - Antiasthmatics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 17/06 - Antipsoriatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

in vitroin vitro.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention provides compositions comprising flagellin polypeptides from bacterial strains and the use of such compositions in the treatment of disease.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The invention provides compositions comprising bacterial strains for stimulating the immune system and treating and preventing diseases.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 37/04 - Immunostimulants
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The invention provides a combination therapy comprising a bacterial strain for treating or preventing cancer.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides a combination therapy comprising a bacterial strain for treating or preventing cancer.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides a combination therapy comprising a bacterial strain for treating or preventing cancer.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides a combination therapy comprising a bacterial strain for treating or preventing cancer.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides compositions comprising bacterial strains and the use of such compositions in the treatment of disease.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/12 - Antidiarrhoeals

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing a neurodegenerative disorder.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing a neurodegenerative disorder.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing neurodegenerative disorders.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention provides compositions comprising commensal bacterial strains and organic acids and the uses thereof in the treatment of diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/203 - Retinoic acids
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing brain injury.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing autoimmune and inflammatory disorders of the central nervous system.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing central nervous system disorders and conditions.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing central nervous system disorders and conditions.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

IPC Classes  ?

• A61P 19/00 - Drugs for skeletal disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 11/06 - Antiasthmatics
• A61P 27/02 - Ophthalmic agents
• A61K 39/08 - Clostridium, e.g. Clostridium tetani
• A61K 35/74 - Bacteria

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 35/00 - Antineoplastic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C12N 1/20 - BacteriaCulture media therefor
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/06 - Antiasthmatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• A61K 35/745 - Bifidobacteria

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C12N 1/20 - BacteriaCulture media therefor
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/06 - Antiasthmatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• A61K 35/745 - Bifidobacteria

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C12N 1/20 - BacteriaCulture media therefor
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/06 - Antiasthmatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• A61K 35/745 - Bifidobacteria

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C12N 1/20 - BacteriaCulture media therefor
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/06 - Antiasthmatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• A61P 27/02 - Ophthalmic agents

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/06 - Antiasthmatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention relates to polypeptide HP, or a polynucleotide sequence encoding polypeptide HP, or a host cell comprising said polynucleotide sequence, or a host cell comprising an expression vector comprising said polynucleotide sequence, for use in the treatment and/or prevention of a disorder in a subject; wherein said disorder is an inflammatory disorder and/or an autoimmune disorder; wherein said polypeptide has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof; and wherein said polynucleotide sequence encodes a polypeptide which has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof and/or wherein said polynucleotide sequence has at least 75% identity to SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5 or variants, homologues, fragments or derivatives thereof.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/02 - Bacterial antigens
• A61K 35/741 - Probiotics
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria

Abstract

The present invention provides a strain of Bacteroides thetaiotaomicron and derivatives thereof, and the use of said strain or derivatives in treating inflammatory, autoimmune and allergic disorders. The invention also provides pharmaceutical compositions, nutritional supplements, feedstuffs, food products, dietary supplements, and food additives comprising said strain or derivatives.

IPC Classes  ?

• A61K 35/74 - Bacteria

Abstract

The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A23L 1/00 - Foods or foodstuffs; Their preparation or treatment (preservation thereof in general A23L 3/00)
• A61K 39/02 - Bacterial antigens
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/00 - Drugs for skeletal disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The invention provides compositions comprising bacterial strains for stimulating the immune system and treating and preventing diseases.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 37/04 - Immunostimulants

Abstract

The invention provides compositions comprising bacterial strains for treating
and preventing
neurodegenerative disorders.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/74 - Bacteria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 1/20 - BacteriaCulture media therefor

Abstract

A composition comprising a bacterial strain of the species Enterococcus durans, for use in a method of treating or preventing a central nervous system disorder or condition.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention provides compositions comprising bacterial strains and the use of such compositions in the treatment of disease, including in central nervous system disorders.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 1/20 - BacteriaCulture media therefor